Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Phase 3 DESTINY-Lung04 shows 14.3-month median PFS for Enhertu in HER2-mutant NSCLC.